Key result
Autoantibodies are associated with the development of atrial fibrillation, potentially playing a pivotal role in the regulation of heart rhythm and the conduction system.
Why the study?
Autoimmunity and autoantibodies are increasingly implicated in AF development, but the exact role of various autoantibodies in AF remains an ongoing debate.
This review highlights the emerging role of autoantibodies in the pathogenesis and prognosis of atrial fibrillation, suggesting potential for novel targeted treatments.
Autoimmunity may inform AF risk stratification; leaves open whether immunomodulation alters disease course pending trials.
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. To date, a lot of research has been conducted to investigate the underlying mechanisms of this disease at both molecular and cellular levels. There is increasing evidence suggesting that autoimmunity is an important factor in the initiation and perpetuation of AF. Autoantibodies are thought to play a pivotal role in the regulation of heart rhythm and the conduction system and, therefore, are associated with AF development. In this review, we have summarized current knowledge concerning the role of autoantibodies in AF development as well as their prognostic and predictive value in this disease. The establishment of the autoantibody profile of separate AF patient groups may appear to be crucial in terms of developing novel treatment approaches for those patients; however, the exact role of various autoantibodies in AF is still a matter of ongoing debate.
No takes yet. Share an insight, caveat, or question.
Zygadło et al. (2023) conducted a review in Atrial fibrillation. Autoantibodies was evaluated. Autoantibodies are associated with the development of atrial fibrillation, potentially playing a pivotal role in the regulation of heart rhythm and the conduction system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: